# Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)

> **NCT03359473** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 97 (actual)

## Conditions studied

- Cachexia

## Interventions

- **DRUG:** GSK2881078
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT03359473
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-28
- **Primary completion:** 2019-11-19
- **Final completion:** 2019-11-19
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2020-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03359473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03359473, "Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03359473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*